A Mushroom-Derived Polysaccharopeptide Engaged CB2-Related Measures in a Rat Morphine Model

A rat inflammatory-pain experiment linked a Trametes versicolor polysaccharopeptide to reduced morphine-related adaptation and changes in CB2-associated measures. It did not test an oral mushroom supplement or establish an adjunctive treatment in patients.

The preparation and route were experimental

Researchers induced inflammatory joint pain and administered morphine intrathecally. The polysaccharopeptide preparation, TPSP, was also administered intrathecally for three weeks. Delivery into the spinal fluid compartment is not equivalent to eating a mushroom or taking a commercially available extract.

Behavioral and molecular outcomes were reported

TPSP reduced reported dependence and acute-withdrawal outcomes and improved mechanical and heat-response measures. These effects accompanied increased CB2 receptor and beta-endorphin measures and reductions in selected inflammatory mediators. The molecular associations do not alone establish that one change fully mediated every behavioral outcome.

Clinical language needs a species boundary

Although the authors proposed an adjunctive strategy, the described experiment used rats. The abstract does not report a clinical trial, demonstrate human safety or identify a suitable consumer preparation. CB2 involvement also does not make TPSP interchangeable with THC or cannabis.

The study is relevant to cannabinoid-system research because a non-cannabis preparation was associated with CB2-related changes. Its actual contribution is preclinical and route-specific. It should not be presented as evidence that an over-the-counter mushroom product prevents opioid tolerance or withdrawal.

Related: interpreting cannabis tolerance claims.

Research cited

Wang K; Wang Z; Cui R; Chu H. Polysaccharopeptide from Trametes versicolor blocks inflammatory osteoarthritis pain-morphine tolerance effects via activating cannabinoid type 2 receptor. International journal of biological macromolecules (2019). doi:10.1016/j.ijbiomac.2018.12.212. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Rat THC–Alcohol Study Found Cross-Tolerance Without Faster Drug Disappearance

A 1979 female-rat study found THC-to-alcohol cross-tolerance on a coordination task without evidence that faster drug disappearance explained the result. The reverse direction was incomplete, so the two exposure histories were not equivalent. The challenge doses were matched by behavioral effect Acute THC and ethanol challenges were selected to reduce…

Spread the love

Read Article: A Rat THC–Alcohol Study Found Cross-Tolerance Without Faster Drug Disappearance

Behavioral THC Tolerance Did Not Eliminate Antibody-Response Suppression in Rats

A 1980 rat study reported behavioral tolerance during oral THC treatment without tolerance to suppression of selected antibody-related responses. The timing of THC relative to antigen exposure also changed the immune result. The immune challenge was experimentally defined Rats received oral THC or vehicle around an antigenic challenge with sheep…

Spread the love

Read Article: Behavioral THC Tolerance Did Not Eliminate Antibody-Response Suppression in Rats

Matched Food-Delivery Schedules Still Produced Different THC Adaptation Patterns in Monkeys

A 1980 squirrel-monkey experiment matched baseline food-delivery patterns yet found schedule-dependent adaptation to THC. The findings offered only partial support for the idea that reinforcement loss alone explains behavioral tolerance. Two response rules produced comparable baseline rewards One component required a long interval between responses, while another used a modified…

Spread the love

Read Article: Matched Food-Delivery Schedules Still Produced Different THC Adaptation Patterns in Monkeys

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us